PRIME THERAPEUTICS

Lobbying client · Minnesota · filed 2025 to 2026

Pharmacy solutions partner for health plans and employers.

$1,480,000 Reported spend

23 Filings counted

3 Outside firms hired

24 Bills named

Spend is reported income plus in-house expenses across 23 filings. 1 further filing for this client was restated by a later amendment and is left out of every total here. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 4 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well.

Who filed for this client 4

PRIME THERAPEUTICS $1,080,000 In-house, the client's own filings · 7 filings
GOVERNMENT COUNSEL, LLC $200,000 Outside firm · 7 filings
STUMPTOWN STRATEGIES $140,000 Outside firm · 7 filings
RED+BLUE STRATEGIES $60,000 Outside firm · 2 filings

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

Bills named in these filings 24

H.R. 2214
DRUG Act

8 filings
H.R. 10445
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025

4 filings
H.R. 5378
Lower Costs, More Transparency Act

4 filings
H.R. 5526
Biosimilar Red Tape Elimination Act

4 filings
S. 526
Pharmacy Benefit Manager Transparency Act of 2025

4 filings
S. 891
Bipartisan Health Care Act

4 filings
H.R. 1227
Alternatives to PAIN Act

3 filings
H.R. 7148
Consolidated Appropriations Act, 2026

3 filings
H.R. 8143
Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026.

3 filings
S. 1954
Biosimilar Red Tape Elimination Act

3 filings
S. 2355
Patients Deserve Price Tags Act

3 filings
S. 3822
Break Up Big Medicine Act

3 filings
H.R. 4317
PBM Reform Act of 2025

2 filings
H.R. 9393
Lower Costs, More Transparency Act of 2026

2 filings
H.R. 1
Lower Energy Costs Act

1 filing
H.R. 9096
Pharmacists Fight Back Act

1 filing
S. 1339
Pharmacy Benefit Manager Reform Act

1 filing
S. 2305
Biosimilar Red Tape Elimination Act

1 filing
H.R. 4231
Treat and Reduce Obesity Act of 2025

1 filing
H.R. 5031
Preserving Patient Access to Long-Term Care Pharmacies Act

1 filing
H.R. 6703
Lower Health Care Premiums for All Americans Act

1 filing
S. 3159
Preserving Patient Access to Long-Term Care Pharmacies Act

1 filing
S. 3345
PBM Price Transparency and Accountability Act

1 filing
S. 832
EPIC Act of 2025

1 filing

Reported by year 2 years

2026 $560,000 11 filings
2025 $920,000 12 filings

Issues lobbied 4

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 4

HOUSE OF REPRESENTATIVES 20
SENATE 20
Health & Human Services, Dept of (HHS) 4
Labor, Dept of (DOL) 2

Recent filings 24 total

Q3 report

RED+BLUE STRATEGIES

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 20, 2026

View → Q3 report

STUMPTOWN STRATEGIES

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $20,000 income · posted Oct 20, 2026

View → Q3 amendment

PRIME THERAPEUTICS

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $140,000 expenses · posted Oct 19, 2026

View → Q3 report

PRIME THERAPEUTICS Amended

3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $140,000 expenses · posted Oct 19, 2026

View → Q3 terminationNo activity

GOVERNMENT COUNSEL, LLC

3rd Quarter 2026 (July 1 - Sep 30) · $20,000 income · posted Aug 18, 2026

View → Registration

RED+BLUE STRATEGIES

3rd Quarter 2026 (July 1 - Sep 30) · posted Aug 13, 2026

View → Q2 report

STUMPTOWN STRATEGIES

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $20,000 income · posted Jul 20, 2026

View → Q2 report

GOVERNMENT COUNSEL, LLC

2nd Quarter 2026 (Apr 1 - June 30) · Senate · $30,000 income · posted Jul 17, 2026

View → Q2 report

PRIME THERAPEUTICS

2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $100,000 expenses · posted Jul 16, 2026

View → Q1 report

PRIME THERAPEUTICS

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $120,000 expenses · posted Apr 20, 2026

View → Q1 report

GOVERNMENT COUNSEL, LLC

1st Quarter 2026 (Jan 1 - Mar 31) · House · $30,000 income · posted Apr 20, 2026

View → Q1 report

STUMPTOWN STRATEGIES

1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $20,000 income · posted Apr 7, 2026

View → Q4 report

PRIME THERAPEUTICS

4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $100,000 expenses · posted Jan 20, 2026

View → Q4 report

STUMPTOWN STRATEGIES

4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $20,000 income · posted Jan 19, 2026

View → Q4 report

GOVERNMENT COUNSEL, LLC

4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $30,000 income · posted Jan 19, 2026

View → Q3 report

STUMPTOWN STRATEGIES

3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $20,000 income · posted Oct 20, 2025

View → Q3 report

PRIME THERAPEUTICS

3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $100,000 expenses · posted Oct 16, 2025

View → Q3 report

GOVERNMENT COUNSEL, LLC

3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $30,000 income · posted Oct 2, 2025

View → Q2 report

STUMPTOWN STRATEGIES

2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $20,000 income · posted Jul 21, 2025

View → Q2 report

PRIME THERAPEUTICS

2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $100,000 expenses · posted Jul 16, 2025

View →

Showing the 20 most recent of 24 filings. Search the explorer for "PRIME THERAPEUTICS".

Keep going

Filings through October 20, 2026, the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.